The study examines two types of eye drops: Monopex (containing dexamethasone phosphate, a steroid medication) and Voltaren ophtha (containing diclofenac sodium, a non-steroidal anti-inflammatory drug). Some patients will receive steroid eye drops, some will receive non-steroid anti-inflammatory drops, and others will receive a combination of both medications. The treatment period lasts for 10 days after the surgery.

The main purpose is to determine which type of anti-inflammatory eye drops works best for controlling eye pressure after trabeculectomy surgery. The study will monitor patients’ eye pressure and other eye health measures for up to 24 months after the surgery. This includes checking vision quality, examining the surgical site, and measuring the thickness of certain parts of the eye using special imaging techniques.

The purpose of the study is to evaluate how this treatment affects the eye’s surface, particularly by looking at changes in the saltiness of tears, known as tear osmolarity. This is important because an increase in tear osmolarity can indicate problems with the eye’s surface. The study will involve patients who have been using at least two different eye pressure-lowering medications for at least two years. Participants will receive the treatment and have their tear osmolarity measured using a simple, painless method that provides immediate results.

The study will take place over a period of time, during which participants will receive the treatment and have their tear osmolarity checked at different points. The goal is to see if the treatment can help improve the condition of the eye’s surface in patients with glaucoma who have been on long-term medication. This research could provide valuable insights into new ways to support eye health in individuals with this condition.

The purpose of the study is to determine if the SLT laser treatment is as effective as the eye drops when used as the first treatment option for a specific type of glaucoma known as exfoliation glaucoma. Participants in the study will be randomly assigned to receive either the laser treatment or the eye drops. The study will monitor the effectiveness of these treatments over a period of time, looking at factors such as the need to add more eye drops, eye dryness, and changes in eye pressure.

The study will also assess the long-term success of the SLT treatment and whether there is a need for further glaucoma surgery. Participants will be followed for a period to observe these outcomes. The goal is to provide valuable information on the best initial treatment approach for managing exfoliation glaucoma and ocular hypertension.

The purpose of the study is to evaluate how effective these eye drops are in relieving symptoms of dry eye disease in patients who also have glaucoma. Participants in the study will be randomly assigned to receive either the Plasma rich in growth factors eye drops or a different preservative-free eye drop formulation. The study is designed to be double-blind, meaning neither the participants nor the researchers will know which treatment each participant is receiving, to ensure unbiased results.

Throughout the study, participants will use the eye drops for a period of up to 12 months. During this time, they will have regular check-ups to monitor changes in their eye condition, such as the degree of eye dryness and any improvements in symptoms. The study will also assess the safety of the treatment by keeping track of any side effects experienced by the participants. The goal is to determine if the Plasma rich in growth factors eye drops can provide a safe and effective treatment option for people suffering from dry eye disease alongside glaucoma.

The purpose of the study is to find out which treatment is most effective in managing eye pressure after surgery. Participants will use the eye drops for a period of up to 10 days following their surgery. The study will monitor the eye pressure of participants over a period of 12 months to assess the effectiveness of the treatments. This will help researchers understand the best way to manage eye pressure after glaucoma surgery and explore the underlying mechanisms of the disease.

Throughout the study, participants will have their eye pressure measured using a method called applanation tonometry, which is a standard way to check the pressure inside the eye. The study will also look at other factors such as changes in vision, the health of the optic nerve, and the success of the surgery over a period of 24 months. This research aims to improve the care and outcomes for patients undergoing surgery for glaucoma.

Participants in the study will receive either the semaglutide tablets or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for several months, during which participants will take the tablets and have regular check-ups to monitor their eye health and overall well-being. The study aims to assess changes in the retina’s function and the progression of glaucoma, as well as the safety and tolerance of semaglutide in patients with this condition.

Throughout the study, participants’ quality of life will also be evaluated using questionnaires. These assessments will help determine if semaglutide can offer additional benefits for people with glaucoma, potentially providing a new approach to protecting the eyes from further damage. The trial is expected to continue until 2028, with recruitment starting in 2024.

The purpose of the study is to determine which anesthetic treatment is more effective in reducing pain during the needling procedure. Participants will receive either the lidocaine gel or the tetracaine/oxybuprocaine eye drops before their procedure. The study will measure the level of pain experienced by patients using a simple numerical scale, as well as the time taken to complete the procedure with each type of anesthetic. Additionally, the study will observe if any patients require additional anesthesia or oral pain relief, and assess the comfort of the surgeon and the patient’s cooperation during the procedure.

This trial aims to provide valuable information on the best anesthetic approach for patients undergoing needling procedures after glaucoma surgery. By comparing the two treatments, the study seeks to improve patient comfort and surgical outcomes in glaucoma care. The trial is expected to conclude by June 2024, with recruitment starting in November 2023.

The purpose of the study is to determine which anesthetic method provides better pain relief and overall satisfaction for patients undergoing these eye procedures. Participants will receive either the lidocaine gel or the tetracaine/oxybuprocaine eye drops before their procedure. The study will monitor the level of pain experienced by patients, as well as the comfort of the surgeon performing the procedure. Additionally, the study will observe any side effects or complications that may occur during or after the procedure.

Throughout the study, researchers will collect information on various factors, such as the number of additional anesthetic drops needed, the condition of the eye’s surface, and the pressure inside the eye, known as intraocular pressure. The study aims to provide valuable insights into which anesthetic method is more effective and satisfactory for patients with glaucoma undergoing these specific eye procedures.